SUNNYVALE, Calif.–(BUSINESS WIRE)–PQ Bypass today announced that data from a subset analysis of the DETOUR I clinical trial will be presented during a late-breaking clinical trial session at Vascular InterVentional Advances (VIVA 17), taking place September 11-14 in Las Vegas. The study evaluated the safety and effectiveness of the DETOUR […]
Author: Ken Dropiewski
Endologix Announces Collaboration Agreements with Japan Lifeline for the Development and Commercialization of Thoracic Endovascular Systems in Japan
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. (“JLL”) pertaining to the development and distribution of novel endovascular […]
VENITI, Inc. Announces Boston Scientific Distribution Agreement For VICI VENOUS STENT®
FREMONT, Calif. and ST. LOUIS, Sept. 11, 2017 /PRNewswire/ — VENITI®, Inc., a leader in the advancement of treatment for deep venous disease, today announced that Boston Scientific will distribute the VICI VENOUS STENT under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed. Launched […]
Abbott is stopping the sale of Absorb first generation BVS in all markets
Time to throw in the towel for Abbott on this generation of their Absorb BVS because of slow sales. However, there could still be a platform for this technology… Abbott halts global sales of 1st-gen Absorb stents SEPTEMBER 8, 2017 BY FINK DENSFORD , MassDevice Abbott (NYSE:ABT) said today it will halt global sales […]
Cerus Endovascular Provides Corporate Update
FREMONT, Calif. and OXFORD, England, Sept. 7, 2017 /PRNewswire/ — Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly differentiated and proprietary interventional neuroradiology devices and delivery systems for the treatment of acute, life-threatening neurological conditions, specifically, intracranial aneurysm, today provided an update on its lead development […]
Micro Interventional Devices Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA Technology
NEWTOWN, Pa., Sept. 7, 2017 /PRNewswire/ — Micro Interventional Devices, Inc.(MID) has successfully completed the first in human tricuspid valve bicuspidization procedure utilizing its MIA (Minimally Invasive Annuloplasty) technology. The successful bicuspidization resulted in a 34.5% reduction in valve area, reducing the patient’s tricuspid regurgitation from severe/moderate to trace. The patient was the […]
Medtronic (MDT) Announces Japanese Regulatory Approval For The IN.PACT Admiral Drug-Coated Balloon
DUBLIN – September 8, 2017 – Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral(TM) Drug-Coated Balloon (DCB) received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg – specifically, in the thigh (superficial femoral arteries (SFA)) and […]
Siemens Healthineers introduces Somatom Confidence RT Pro CT Scanner
Erlangen, 2016-Sep-27 Somatom Confidence RT Pro is a dedicated CT for radiation therapy DirectDensity algorithm delivers electron density images independent of kV settings, ensuring a smooth simple dose calculation workflow New version of syngo.via RT Image Suite software offers advanced treatment of moving tumors Siemens Healthineers introduced its new Somatom […]
Biotech Pioneer BIOLIFE4D Submits Regulation A+ Filing with SEC for up to $50 Million Initial Public Offering
CHICAGO, Sept. 7, 2017 /PRNewswire/ — BIOLIFE4D announced it filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. Chicago-based BIOLIFE4D is a pioneering biotech company focused on leveraging […]
BioCardia Receives U.S. Patent Covering A Method Of Preparing And Characterizing Mesenchymal Cells, Providing Further Protection To Cardiallo Cell Therapy Program
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, with clinical programs in heart failure and sub-acute infarction, today announced the issuance of United States Patent No. 9,301,975 relating to a method of producing mesenchymal stem cells from bone marrow cells in […]



